Literature DB >> 26034135

Mobilization of epithelial mesenchymal transition genes distinguishes active from inactive lesional tissue in patients with ulcerative colitis.

Xinmei Zhao1, Jinshui Fan2, Fachao Zhi3, Aimin Li4, Chen Li3, Alan E Berger2, Meher Preethi Boorgula2, Sangjucta Barkataki2, Jean-Paul Courneya2, Yuqing Chen3, Kathleen C Barnes2, Chris Cheadle5.   

Abstract

Ulcerative colitis (UC) is a chronic, relapsing and debilitating idiopathic inflammation, with variable and complex pathophysiologies. Our objective was to elucidate patterns of gene expression underlying the progression of UC disease. Single endoscopic pinch FFPE biopsies (n = 41) were sampled at both active and inactive stages at the same site in individual UC patients and compared with each other and with non-inflammatory bowel disease healthy controls. Gene expression results were validated by quantitative reverse transcriptase-PCR (QRT-PCR), and results at the protein level were validated by immunohistochemistry and western blot. Analysis of microarray results demonstrated that UC patients in remission display an intermediate gene expression phenotype between active UC patients and controls. It is clear that UC active site recovery does not revert fully back to a healthy control phenotype. Both UC active and inactive tissue displayed evidence, at both the gene expression and protein level, of a positive precancerous state as indicated by increases in the expression of Chitinase 3-Like-1, and the colorectal cancer metastasis marker MMP1. A key distinguishing feature between active and inactive UC, however, was the mobilization of marker genes and proteins for the Epithelial Mesenchymal Transition (EMT) pathway only in active UC. Analysis of the gene expression signatures associated with UC remission identified multiple pathways which appear to be permanently dysregulated in UC patients at formerly active sites in spite of clear histological recovery. Among these pathways, the EMT pathway was specifically up-regulated only in active UC emphasizing the potential for cancer progression in these patients.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26034135     DOI: 10.1093/hmg/ddv192

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

Review 1.  Systematic review of the old and new concepts in the epithelial-mesenchymal transition of colorectal cancer.

Authors:  Simona Gurzu; Camelia Silveanu; Annamaria Fetyko; Vlad Butiurca; Zsolt Kovacs; Ioan Jung
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

2.  GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis.

Authors:  Nitish Rana; Giuseppe Privitera; Hannah C Kondolf; Katarzyna Bulek; Susana Lechuga; Carlo De Salvo; Daniele Corridoni; Agne Antanaviciute; Rebecca L Maywald; Alexander M Hurtado; Junjie Zhao; Emina H Huang; Xiaoxia Li; E Ricky Chan; Alison Simmons; Giorgos Bamias; Derek W Abbott; Jason D Heaney; Andrei I Ivanov; Theresa T Pizarro
Journal:  Cell       Date:  2022-01-11       Impact factor: 41.582

3.  Mass Cytometry and Single-Cell Transcriptome Analyses Reveal the Immune Cell Characteristics of Ulcerative Colitis.

Authors:  Yongxin Luo; Shiying Liu; Huibiao Li; Jiangtao Hou; Wenjia Lin; Zewen Xu; Tianyu Lu; Yanwu Li; Bin Peng; Shijing Zhang; Xue Han; Zuoliang Kuang; Yi Wen; Jiazhong Cai; Fengbin Liu; Xin-Lin Chen
Journal:  Front Mol Biosci       Date:  2022-06-23

4.  Identification of potential biomarkers and pathways in ulcerative colitis with combined public mRNA and miRNA expression microarray data analysis.

Authors:  Lili Yang; Yaoyao Bian; Zhengjun Li; Yan Yan; Junyi Li; Wenlin Li; Li Zeng
Journal:  J Gastrointest Oncol       Date:  2019-10

5.  Epithelial-derived gasdermin D mediates nonlytic IL-1β release during experimental colitis.

Authors:  Katarzyna Bulek; Junjie Zhao; Yun Liao; Nitish Rana; Daniele Corridoni; Agne Antanaviciute; Xing Chen; Han Wang; Wen Qian; William A Miller-Little; Shadi Swaidani; Fangqiang Tang; Belinda B Willard; Keith McCrae; Zizhen Kang; George R Dubyak; Fabio Cominelli; Alison Simmons; Theresa T Pizarro; Xiaoxia Li
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

6.  Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation.

Authors:  Patrícia Oliveira; Joana Carvalho; Sara Rocha; Mafalda Azevedo; Inês Reis; Vânia Camilo; Bárbara Sousa; Sofia Valente; Joana Paredes; Raquel Almeida; David Huntsman; Carla Oliveira
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

7.  Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1.

Authors:  Jiansong Wu; Qiang Niu; Jie Yuan; Xiaodan Xu; Liuxia Cao
Journal:  Exp Ther Med       Date:  2019-10-07       Impact factor: 2.447

8.  BMAL1 Knockdown Leans Epithelial-Mesenchymal Balance toward Epithelial Properties and Decreases the Chemoresistance of Colon Carcinoma Cells.

Authors:  Yuan Zhang; Aurore Devocelle; Christophe Desterke; Lucas Eduardo Botelho de Souza; Éva Hadadi; Hervé Acloque; Adlen Foudi; Yao Xiang; Annabelle Ballesta; Yunhua Chang; Julien Giron-Michel
Journal:  Int J Mol Sci       Date:  2021-05-16       Impact factor: 5.923

9.  Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation.

Authors:  Anne-France Le Rolle; Thang K Chiu; Zhaoshi Zeng; Jinru Shia; Martin R Weiser; Philip B Paty; Vi K Chiu
Journal:  Oncotarget       Date:  2016-01-19

10.  Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease.

Authors:  Debashis Sahoo; Lee Swanson; Ibrahim M Sayed; Gajanan D Katkar; Stella-Rita Ibeawuchi; Yash Mittal; Rama F Pranadinata; Courtney Tindle; Mackenzie Fuller; Dominik L Stec; John T Chang; William J Sandborn; Soumita Das; Pradipta Ghosh
Journal:  Nat Commun       Date:  2021-07-12       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.